Filing Overview
Registrant: Tivic Health Systems, Inc. The request metadata identifies Valion Bio, Inc., but the provided Form 8-K is filed by Tivic Health Systems, Inc. and relates to events beginning July 14, 2023. The offering closed on July 19, 2023.
Business Context and Reporting Period
This Form 8-K reports the launch and closing of a public offering of common stock, related placement-agent compensation, and the issuance of unregistered placement-agent warrants. No quarterly or annual operating results are reported.
Transaction and Key Financial Metrics
- The company sold 51,250,000 shares of common stock at $0.040 per share.
- Gross offering proceeds were approximately $2.1 million.
- Estimated net proceeds were approximately $1.9 million after placement-agent fees, expenses, and other estimated offering costs.
- The placement agent received an 8.0% cash fee of $164,000 and reimbursement of certain expenses of up to $90,000.
- The company issued warrants to purchase up to 2,050,000 shares, equal to 4.0% of the shares placed.
- The warrants have a five-year term, become exercisable six months after closing, and have an exercise price of $0.048 per share.
- Management stated that net proceeds will be used for working capital and general corporate purposes.
- The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity balances for a comparable period.
Material Changes Versus the Prior Comparable Period
The filing does not present prior-period financial statements or operating comparisons. The material change disclosed is the issuance of 51.25 million common shares and potential issuance of 2.05 million additional shares upon exercise of the placement-agent warrants, resulting in equity dilution for existing holders.
Guidance, Outlook, Risks, and Unusual Items
- No quantitative financial guidance or operating forecast is provided.
- The proceeds are intended to support working capital and general corporate needs; specific allocation by project or expense category is not disclosed.
- The placement-agent warrants and potential future exercise proceeds create additional potential dilution.
- The company agreed to a 30-day restriction on issuing, agreeing to issue, or announcing proposed issuances of securities, subject to exceptions.
- Officers and directors entered into 30-day lock-up agreements covering securities they hold, subject to exceptions.
- The warrants and shares issuable upon exercise were issued under an exemption from Securities Act registration pursuant to Section 4(a)(2) and/or Regulation D.
- The Purchase Agreement includes customary closing conditions, representations, warranties, indemnification obligations, termination rights, and ongoing covenants.
Important Facts for Investors to Verify
- Confirm the registrant identity, because the supplied metadata names Valion Bio, Inc., while the filing names Tivic Health Systems, Inc.
- Verify the final number of shares sold and the actual net proceeds after all offering expenses.
- Review the company’s capitalization table to assess dilution from the 51.25 million shares and 2.05 million placement-agent warrants.
- Review the warrant terms, including the six-month exercise delay, $0.048 exercise price, and five-year term.
- Assess the company’s liquidity and cash runway using subsequent periodic filings, as this Form 8-K does not provide cash balances or operating cash-flow information.
- Review Exhibits 10.1, 10.2, and 4.1 for the complete contractual terms and restrictions.